# New chemotherapy regimens and biomarkers for Chagas disease

> **NIH NIH U01** · UNIVERSITY OF TEXAS EL PASO · 2022 · $1,214,881

## Abstract

ABSTRACT
Chagas disease is caused by the parasite, Trypanosoma cruzi, and affects millions of people in Latin America.
Lately, Chagas disease has become an emerging worldwide public health issue due to globalization. Chagas
disease has two phases: an initial acute phase, usually with nonspecific symptoms or asymptomatic, and a
lifelong chronic phase, which is clinically silent or indeterminate in 60-70% of patients. However, 30-40% of
chronic patients will eventually develop heart and/or digestive complications. Currently, the only approved
drugs for treating Chagas disease are benznidazole (BZN) and nifurtimox (NFX). The efficacy of these drugs is
variable and depends on the disease stage, drug dose, age of patients, and infecting T. cruzi strain(s).
Treatment in the acute phase is effective with both drugs. However, the efficacy of these drugs in adults with
chronic, long-established infections is significantly lower and variable. Moreover, the high rate of adverse
events of these drugs has hampered their regular clinical use, thus <1% of patients are being treated. In this
project, we propose to test four new dosing regimens of BZN and NFX. Our first hypothesis is that a lower
frequency of BZN and NFX dosing, with standard or extended treatment duration, might have the same or
better efficacy than the standard treatment regimens with these drugs, with fewer adverse events. Here, we
plan to analyze current and novel host- and parasite-derived BMKs that have shown promising results in pilot,
full clinical trials or in animal studies, providing a measure of disease state and cure. Thus, our second
hypothesis is that in those patients that respond to BZN or NFX treatment the serum levels of one or more
proposed BMKs will be significantly reduced or become negative within three years post-treatment. To test
these two hypotheses, we propose two specific aims: Specific Aim 1: To determine the safety and efficacy of
extended benznidazole or nifurtimox treatment regimens with lower dosing frequency. Specific Aim 2: To
evaluate host- and parasite-derived biomarkers for the follow-up of Chagas disease chemotherapy. The
information gained in this project would also allow for better-designed clinical trials with previously proposed
drug combinations, in which BZN and NFX would play a central role.

## Key facts

- **NIH application ID:** 10469327
- **Project number:** 5U01AI129783-05
- **Recipient organization:** UNIVERSITY OF TEXAS EL PASO
- **Principal Investigator:** IGOR C ALMEIDA
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,214,881
- **Award type:** 5
- **Project period:** 2018-08-17 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10469327

## Citation

> US National Institutes of Health, RePORTER application 10469327, New chemotherapy regimens and biomarkers for Chagas disease (5U01AI129783-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10469327. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*